Fundamental Analysis of BIODEXA PHARMACEUTICALS-ADR(NASDAQ:BDRX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BDRX. BDRX was compared to 565 industry peers in the Biotechnology industry. BDRX has a bad profitability rating. Also its financial health evaluation is rather negative. BDRX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

BDRX had negative earnings in the past year.

In the past year BDRX has reported a negative cash flow from operations.

BDRX had negative earnings in each of the past 5 years.

BDRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -48.82%, BDRX perfoms like the industry average, outperforming 49.02% of the companies in the same industry.

Looking at the Return On Equity, with a value of -78.14%, BDRX is in line with its industry, outperforming 52.41% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-48.82%
ROE	-78.14%
ROIC	N/A

ROA(3y)-82.67%

ROA(5y)-101.33%

ROE(3y)-148.56%

ROE(5y)-165.51%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

BDRX has more shares outstanding than it did 1 year ago.

BDRX has a better debt/assets ratio than last year.

2.2 Solvency

BDRX has an Altman-Z score of -5.62. This is a bad value and indicates that BDRX is not financially healthy and even has some risk of bankruptcy.

BDRX has a worse Altman-Z score (-5.62) than 63.99% of its industry peers.

BDRX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

BDRX has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	-5.62

ROIC/WACCN/A

WACC8.77%

2.3 Liquidity

BDRX has a Current Ratio of 2.16. This indicates that BDRX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.16, BDRX is doing worse than 74.51% of the companies in the same industry.

BDRX has a Quick Ratio of 2.16. This indicates that BDRX is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of BDRX (2.16) is worse than 73.26% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.16
Quick Ratio	2.16

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.40% over the past year.

The Revenue for BDRX has decreased by -84.31% in the past year. This is quite bad

BDRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.56% yearly.

EPS 1Y (TTM)83.4%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%97.2%

Revenue 1Y (TTM)-84.31%

Revenue growth 3Y3.56%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

BDRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.85% yearly.

BDRX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -73.70% yearly.

EPS Next Y80.32%

EPS Next 2Y36.71%

EPS Next 3Y22.81%

EPS Next 5Y18.85%

Revenue Next Year-94.72%

Revenue Next 2Y-83.75%

Revenue Next 3Y-76.99%

Revenue Next 5Y-73.7%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BDRX. In the last year negative earnings were reported.

Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BDRX's earnings are expected to grow with 22.81% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.71%

EPS Next 3Y22.81%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BDRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (11/21/2024, 8:14:32 PM)

After market: 4.45 +0.05 (+1.14%)

4.4

+0.55 (+14.29%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap63.89M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.82%
ROE	-78.14%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.16
Quick Ratio	2.16
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)83.4%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y80.32%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-84.31%

Revenue growth 3Y3.56%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIODEXA PHARMACEUTICALS-ADR (BDRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens